Acknowledgements Medical writing and editorial assistance was provided by Andy Bond and Emma Marshman of Spirit Medical Communications Ltd, and was supported by Novo Nordisk A/S. The authors would like to thank all subjects who participated in this trial. We also acknowledge the trial investigators: A ´ gnes Re´thy (Pe´terfy Sa´ndor utcai Ko´rha´z, Budapest, Hungary), Istva´n Kiss and Szent Imre Egyetemi Oktato´ko´rha´z, Budapest, Hungary), Petr Sˇra´mek (Pharmaceutical Research Associates CZ, s.r.o. Prague, Czech Republic) and Sylvia Dusilova´-Sulkova´ (Hemodialyzacˇnı´ strˇedisko, Hradec Kra´love´-Novy´ Hradec Kra´love´, Czech Republic); Michael Pilgaard Andersen (Novo Nordisk A/S) for support with the semaglutide and SNAC bioanalyses; and Morten Donsmark and Salvatore Calanna (Novo Nordisk A/S) for their review of the manuscript. 